

# Kilannin Krysiak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5410734/publications.pdf>

Version: 2024-02-01

39  
papers

2,923  
citations

361413

20  
h-index

315739

38  
g-index

53  
all docs

53  
docs citations

53  
times ranked

7210  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	1.4	17
2	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). <i>Genetics in Medicine</i> , 2022, 24, 986-998.	2.4	55
3	Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease. <i>Human Mutation</i> , 2022, 43, 1268-1285.	2.5	6
4	Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers. <i>Cancer Genetics</i> , 2022, 264-265, 90-99.	0.4	3
5	A community approach to the cancer-variant-interpretation bottleneck. <i>Nature Cancer</i> , 2022, 3, 522-525.	13.2	3
6	Heterozygous <i>HMGB1</i> loss-of-function variants are associated with developmental delay and microcephaly. <i>Clinical Genetics</i> , 2021, 100, 386-395.	2.0	3
7	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203.	3.0	4
8	Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice. <i>Leukemia Research</i> , 2020, 96, 106428.	0.8	5
9	CIViCpy: A Python Software Development and Analysis Toolkit for the CIViC Knowledgebase. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 245-253.	2.1	10
10	A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. <i>Nature Genetics</i> , 2020, 52, 448-457.	21.4	104
11	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). <i>Blood</i> , 2020, 136, 23-23.	1.4	0
12	A Spontaneous Aggressive ER <sup>+</sup> Mammary Tumor Model Is Driven by Kras Activation. <i>Cell Reports</i> , 2019, 28, 1526-1537.e4.	6.4	19
13	Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	2.1	6
14	Standard operating procedure for curation and clinical interpretation of variants in cancer. <i>Genome Medicine</i> , 2019, 11, 76.	8.2	16
15	Text-mining clinically relevant cancer biomarkers for curation into the CIViC database. <i>Genome Medicine</i> , 2019, 11, 78.	8.2	35
16	Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples. <i>Genetics in Medicine</i> , 2019, 21, 972-981.	2.4	67
17	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.	1.4	130
18	Adapting crowdsourced clinical cancer curation in CIViC to the ClinGen minimum variant level data community-driven standards. <i>Human Mutation</i> , 2018, 39, 1721-1732.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3787.	12.8	112
20	The prognostic effects of somatic mutations in ER-positive breast cancer. <i>Nature Communications</i> , 2018, 9, 3476.	12.8	89
21	CIVIC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. <i>Nature Genetics</i> , 2017, 49, 170-174.	21.4	460
22	Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. <i>Bone</i> , 2017, 101, 145-155.	2.9	37
23	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017, 129, 473-483.	1.4	147
24	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	7.0	66
25	Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells. <i>PLoS ONE</i> , 2017, 12, e0170470.	2.5	23
26	DGIdb 2.0: mining clinically relevant drug-gene interactions. <i>Nucleic Acids Research</i> , 2016, 44, D1036-D1044.	14.5	359
27	Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. <i>Cell Reports</i> , 2016, 17, 249-260.	6.4	21
28	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. <i>Experimental Hematology</i> , 2016, 44, 603-613.	0.4	44
29	Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors. <i>Blood</i> , 2016, 128, 5285-5285.	1.4	0
30	Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis. <i>Blood</i> , 2016, 128, 4306-4306.	1.4	0
31	Optimizing Cancer Genome Sequencing and Analysis. <i>Cell Systems</i> , 2015, 1, 210-223.	6.2	174
32	Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells. <i>Experimental Hematology</i> , 2015, 43, 319-330.e10.	0.4	15
33	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015, 126, 574-574.	1.4	2
34	Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. <i>Nature Genetics</i> , 2012, 44, 53-57.	21.4	513
35	Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. <i>Blood</i> , 2011, 117, 1530-1539.	1.4	72
36	Lipophilic Pyridinium Bisphosphonates: Potent $\hat{3}$ T Cell Stimulators. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 1136-1138.	13.8	63

#	ARTICLE	IF	CITATIONS
37	Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation. <i>Journal of the American Chemical Society</i> , 2009, 131, 5153-5162.	13.7	159
38	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: A QSAR investigation. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8959-8967.	3.0	22
39	Activity of Sulfonium Bisphosphonates on Tumor Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6067-6079.	6.4	15